APD334-003 (S1P1 receptor antagonist) in UC

Print

Details of Research

Contact: Shelley Mikolainis, Research Coordinator
416-586-4800 ext 4989
smikolainis@mtsinai.on.ca

Primary Investigator: Dr. Hillary Steinhart

Enrolment: Ongoing

Expectations: oral once daily, (1 mg, 2 mg or placebo), may be eligible open label study

Eligibility

  • Mayo score (3 component) 4-9 (bleeding subscore >1)
  • inadequate response, loss of response to or intolerance to 5-ASA,  immunomodulators/steroids, TNF?, or integrin antagonists within past 5 years
  • TNF?, or integrin antagonists washout is 60 days prior to Day 1
  • immunosuppresants are discontinued at Day 1


Exclusions
: previous treatment with more than 2 biologic agents, history of retinal macular edema

WE INVITE YOU TO PARTNER WITH US TODAY
Donate to the Zane Cohen Centre
Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Joseph and Wolf Lebovic Health Complex. Copyright © 1997 - 2017.
All Rights Reserved. A patient care, teaching and research centre affiliated with University of Toronto.
Powered by Joomla 1.7 Templates